Business Context and Reporting Period
Company: Galectin Therapeutics Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: May 23, 2013
Context: This filing serves as a Regulation FD disclosure to provide an updated telephone number for accessing the audio portion of the presentation following the Company's 2013 Annual Meeting of Shareholders.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is an administrative update regarding shareholder meeting logistics and does not contain financial statements or performance data.
Material Changes
No material financial or operational changes are reported in this document. The only change disclosed is the correction of the toll-free and international phone numbers for the shareholder meeting audio presentation.
Guidance, Outlook, and Risks
Management Commentary: The filing explicitly states that the information is being furnished and not filed for purposes of Section 18 of the Securities Exchange Act of 1934. It shall not be deemed incorporated by reference in any other filing unless expressly set forth by specific reference.
Risks and Contingencies: No new risks or contingencies are disclosed in this specific report.
Investor Verification Checklist
- Verify the correct audio access numbers for the 2013 Annual Meeting: (888) 582-3528 (US toll-free) or (847) 944-7361 (International).
- Confirm the passcode for the presentation remains 7827311#.
- Note that this 8-K does not contain financial results; refer to the most recent 10-K or 10-Q for financial data.